Scientific Advisory Board

To augment our science team’s capabilities, we have created a Scientific Advisory Board. These individuals have deep experience in a variety of areas.

Scientific Advisory Board

Manfred Auer, Ph.D.

Dr. Auer is Research Professor of Chemical and Translational Biology of the Scottish Universities Life Sciences Alliance at the University of Edinburgh. In his lab, he links basic research and applied science by developing and running new miniaturized target, compound and technology platforms comprising all steps from design, theoretical and experimental target analysis, high throughput chemical synthesis and screening, to quantitative mechanistic studies of compound action in cells and model organisms. Before moving to academia, Dr. Auer spent twenty years in the pharmaceutical industry, including service as Executive Director of the Innovative Screening Technologies unit within the Novartis Institutes for Biomedical Research.

Adam Brufsky M.D., Ph.D.

Dr. Brufsky is Professor of Medicine at the University of Pittsburgh School of Medicine and serves as the Associate Division Chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine’s Department of Medicine. Dr. Brufsky is the Medical Director of the Magee-Women’s Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; Associate Director for Clinical Investigations at UPMC Hillman Cancer Center; and Co-Director of the Comprehensive Breast Cancer Center. An active researcher, Dr. Brufsky has numerous abstracts and research articles in leading journals, and is Principal Investigator on several research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army – Breast Cancer Research Program.

Edward Greeno, M.D.

Dr. Greeno is Medical Director of the Hematology/Oncology Clinic at the University of Minnesota and an Associate Professor at the University of Minnesota Medical School. He has been listed as one of the Best Doctors in America for a number for years.

Sara Hurvitz, M.D.

Dr. Hurvitz is Director, Breast Cancer Clinical Research Programs at the Geffen School of Medicine at UCLA and an Assistant Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA.  She is also the Co-Director of the Santa Monica-UCLA Outpatient Hematology/Oncology Practice and Medical Director of the Jonsson Comprehensive Cancer Center Clinical Research Unit. Dr. Hurvitz is interested in designing and implementing phase I and II (translational) breast cancer clinical trials. Dr. Hurvitz is also interested in studying the gene expression patterns in a variety of breast cancer populations, and evaluating these patterns to detect new subtypes of breast cancer that may be more accurately targeted by novel therapies.

Benita Katzenellenbogen, Ph.D.

Dr. Katzenellenbogen is the Swanlund Professor of Molecular and Integrative Physiology and the Swanlund Professor of Cell and Developmental Biology at the University of Illinois School of Molecular and Cellular Biology. Her research interests include regulation of gene expression, signal transduction, and cell proliferation and phenotypic properties by hormones and growth factors as well as biomarker discovery and cellular changes underlying resistance to therapeutic agents in breast cancer.

John Katzenellengogen, Ph.D.

Dr. Katzenellenbogen is Research Professor of Chemistry at the University of Illinois, an Affiliate of the Beckman Institute and Department of Bioengineering, and a Fellow of the American Academy of Arts and Sciences. His research has focused on aspects of the structure, function, and the use of steroid receptors, and includes biochemical and biophysical studies on the dynamics of the estrogen receptors and their interaction with coregulator proteins.

Carol Lange, Ph.D.

Dr. Lange is Professor of Medicine and Pharmacology at the University of Minnesota. She is also Endowed Chair of the Tickle Family Land Grant in Breast Cancer Research and Director of the Women’s Cancer Program at the University of Minnesota. Dr. Lange studies the molecular biology of breast cancer. Her laboratory is focused on the study of cross-talk between peptide growth factors and steroid hormone receptors in human breast cancer cells, with the goal of developing better strategies for the treatment of breast and other hormonally influenced and/or epithelial cell-derived cancers.

Stanley Marks, M.D.

Dr. Marks is Chairman of the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center and serves as Chief of the Division of Hematology/Oncology at UPMC Shadyside. Dr. Marks also is the Medical Director of Forbes Hospice and Clinical Associate Professor of Medicine at the University of Pittsburgh School of Medicine. Dr. Marks served as President of The Leukemia & Lymphoma Society and President and Chairman of the Allegheny County Medical Society. He served on the Board of directors of the American Cancer Society. Dr. Marks has authored numerous publications.

Ron McGlennen, M.D.

Dr. McGlennen is President and Medical Director of Access Genetics, a molecular diagnostics company he cofounded in 2001. Previously he was an Associate Professor at the University of Minnesota. He also serves as Celcuity’s Medical Director.

Mark Pegram, M.D., Ph.D.

Dr. Pegram is the first director of the Breast Cancer Oncology Program at Stanford Women’s Cancer Center, and the co-director of Stanford’s Molecular Therapeutics Program. Dr. Pegram commitment to translational science includes having played a major role in developing the drug Herceptin® as a treatment for HER2-positive breast cancer. His laboratory experiments demonstrated that combining Herceptin with chemotherapy effectively killed cancer cells that overproduced the growth factor HER2. Dr. Pegram and others then conducted clinical trials showing that Herceptin improved survival rates and even cured some breast cancer patients. Dr. Pegram’s current research efforts include a continued focus on the cancer-associated gene that encodes HER2 and developing new ways to target cancer cells expressing this protein. Dr. Pegram has numerous publications to his credit.

Mothaffar F. Rimawi, M.D.

Dr. Rimawi is an Associate Professor and Director of Clinical Research at the Lester and Sue Smith Breast Center at Baylor College of Medicine. He also serves as the Executive Medical Director and Co-Leader of the Breast Cancer Program at the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine. His research is focused on translating laboratory findings to the clinic to develop new treatments for breast cancer.

Lee S. Schwartzberg, M.D., FACP

Dr. Schwartzberg is the Executive Director of West Cancer Center and founding member of West Clinic, a multispecialty oncology practice affiliated with the University of Tennessee. He also serves as Professor of Medicine and Division Chief of Hematology/Oncology at The University of Tennessee Health Science Center. His major research interests are new therapeutic approaches to breast cancer, targeted therapy and supportive care. He has published more than 150 research papers during his oncology career.